Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Australian Floating Rate ETF (FLOT) vs Medpace Holdings Inc (MEDP) Price & Performance

VanEck Australian Floating Rate ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

VanEck Australian Floating Rate ETF vs Medpace Holdings Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.94, while Medpace Holdings Inc trades at $599.46 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.

FLOTMEDP
Sector
Sector/ThematicTechnology
52-Week High
$51.09$620.59
52-Week Low
$50.72$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Australian Floating Rate ETF

FLOT trades at $50.93 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy decisions and their impact on floating rate bonds amid persistent inflation concerns.

FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a conservative income vehicle. The ETF benefits from potential Fed rate hikes but faces headwinds from inflation volatility and Treasury yield fluctuations. Current technical weakness suggests cautious near-term positioning despite the defensive characteristics of floating rate securities.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Australian Floating Rate ETF

FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.

Read more on FLOT

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP